Ireland
--:--IST
Enrolling by invitation Not applicable

Medium-term Effects of a Polyphenol-rich Beverage Based on Red Grape Pomace Extract on Non-alcoholic Fatty Liver Disease, Cardiometabolic Risk Profile and Gut Microbiota in Subjects with Type 2 Diabetes

NCT06895018 · tracked via the Priya Life Science Italy tracker
Phase
Not applicable
Started
2024-05-03
Last updated
2025-03-26

Condition(s) studied

Diabetes Mellitus Type 2

Investigational drug(s) / intervention(s)

Supplementation with Polyphenol Rich DrinkSupplementation with Control Drink (Placebo)

Supplementation with Polyphenol Rich Drink: Participants were instructed to consume, over a 6-week period, within the context of a Mediterranean diet, a polyphenol-rich drink RGPD (150 mL) containing 1.5 g of polyphenols. After this treatment period, participants underwent a two-week washout period before switching to the alternative treatment with control drink (Placebo) devoid of polyphenols. To evaluate metabolic responses during both fasting and postprandial states, participants participants consumed a standardized test meal at the end of the 6 weeks. This standard meal was preceded by the consumption of the RGPD 60 minutes prior.

Supplementation with Control Drink (Placebo): Participants were instructed to consume, over a 6-week period, within the context of a Mediterranean diet, a control drink (Placebo) (150 mL) containing 0 g of polyphenols. After this treatment period, participants underwent a two-week washout period before switching to the alternative treatment with a polyphenol-rich drink RGPD (150 mL) containing 1.5 g of polyphenols. To evaluate metabolic responses during both fasting and postprandial states, participants participants consumed a standardized test meal at the end of the 6 weeks. This standard meal was preceded by the consumption of the Control drink (Placebo) 60 minutes prior.

Study summary

Nonalcoholic fatty liver disease (NAFLD) is a liver disease characterized by an abnormal accumulation of fat not due to alcohol or drug consumption that can evolve into steatohepatitis (NASH), fibrosis and cirrhosis. Its prevalence is high, affecting approximately 20-30% of the general adult population and is also growing in pediatric age. Obesity, insulin resistance and type 2 diabetes (T2DM) are common and well-known risk factors for NAFLD, which is approximately 2-3 times more prevalent among obese and diabetic individuals. Despite the high and increasing prevalence of NAFLD in the population, its pathophysiology is not fully understood and there is currently no pharmacological treatment available.

Recent evidence suggests that dietary polyphenols may have specific beneficial effects on hepatic steatosis and associated sequelae by polyphenol metabolites and their phase II derivatives. Therefore, the aim of our study is to evaluate whether medium-term consumption of a beverage rich in polyphenols extracted from red grape pomace is able to exert beneficial effects on hepatic steatosis, cardiometabolic risk profile and microbiota composition of patients with type 2 diabetes.

Eligibility

Sex
MALE
Min age
35 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Body Mass Index (BMI) \>25 and ≤35 kg/m2 * Cholesterolemia ≤ 250 mg/dl and Triglyceridemia ≤ 200 mg/dl. * type 2 Diabetes in good glycemic control (Hb1Ac ≤7.5%) treated with diet alone or diet + metformin. Exclusion Criteria: * Cardiovascular events (myocardial infarction and/or stroke) * Renal insufficiency (serum creatinine \>1.5 mg/dl) and liver failure (ALT/AST twice the normal values) * Anemia (Hb \<12 g/dl) or other chronic disease * Insulin therapy and other hypoglycemic drugs other than metformin * Habitual intense physical activity

Primary outcome measure(s)

  • Differences in liver fat content — At baseline and at the end of 6 weeks of each treatment
    Differences in liver fat content after the intake of polyphenol rich drink (RGPD) for 6 weeks, as compared to Control drink (Placebo). Liver fat content will be assessed by magnetic resonance spectroscopy (MRI).

Trial sites (1)

FacilityCityRegionStatus
Federico II University Naples Italy
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06895018 on ClinicalTrials.gov ↗ ← All trials in Italy